Review highlights immunotherapy of advanced melanoma with immune checkpoint inhibition

  • April 15, 2014

NEW YORK – Steven J. O’Day, MD, reviews the current role of immune checkpoint inhibitors, such as ipilimumab as well as monoclonal antibodies targeting the PD-1 protein or its ligand, PD-L1, in the treatment of advanced melanoma.

O’Day notes that while these two checkpoint inhibitors have the potential to transform metastatic melanoma treatment, there are nevertheless severe immune-related side effects that need be closely managed in patients. In addition, more research needs to be performed on whether checkpoint inhibitors should be used in combination or in sequence to maximize efficacy while to adequately controlling side effects.

Full Story »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

More »
  • Meeting News Coverage
  • OSN meeting
  • WOC 2014
  • Coverage from the World Ophthalmology Congress in Tokyo.
More »
  • Health Care Update
  • ARNOLD AND PORTER SILO
  • ICD-10 delayed
  • Dismay or relief greet latest ICD-10 implementation delay. Analysis by Catherine A. Brandon of Arnold & Porter LLP.
More »
More »
More »
More »